Helmholtz Gemeinschaft


Definition and quantification of six immune- and neuroregulatory serum proteins in healthy and demented elderly

Item Type:Article
Title:Definition and quantification of six immune- and neuroregulatory serum proteins in healthy and demented elderly
Creators Name:Schipke, C.G. and Günter, O. and Weinert, C. and Scotton, P. and Sigle, J.P. and Kallarackal, J. and Kabelitz, D. and Finzen, A. and Feuerhelm-Heidl, A.
Abstract:AIM: Blood-based biomarkers related to immune- and neuroregulatory processes may be indicative of dementia but lack standardization and proof-of-principle studies. MATERIALS & METHODS: The blood serum collection protocol as well as the analytic procedure to quantify the markers BDNF, IGF-1, VEGF, TGF-β 1, MCP-1 and IL-18 in blood serum were standardized and their concentrations were compared between groups of 81 Alzheimer’s disease patients and 79 healthy controls. RESULTS: Applying standardized methods, results for the quantification of the six markers in blood serum are stable and their concentrations significantly differ for all analytes except VEGF between patients diagnosed with Alzheimer’s disease and healthy controls. CONCLUSION: Analyzing a panel of six markers in blood serum under standardized conditions may serve as a diagnostic tool in primary dementia care in the future. LAY ABSTRACT: Neurodegenerative processes underlie and account for a large portion of dementia cases in the elderly, with Alzheimer’s disease being the most common neurodegenerative disorder. Yet, it is challenging for nonspecialized physicians to assess whether a patients’ cognitive impairment originates in underlying neurodegenerative processes. We show that the combination of six biomarkers quantified in blood can indicate the presence of Alzheimer’s disease, since these markers are not altered in healthy elderly people. Blood biomarkers indicative of neurodegenerative processes may be useful in the future to compile a personalized diagnostic and treatment plan to assess the basis of, and properly treat, cognitive impairment.
Keywords:Alzheimer's Disease, Biomarker, Blood Serum, Clinical Diagnosis, Cytokines, Dementia, Inflammation, Neurodegeneration
Source:Neurodegenerative Disease Management
Publisher:Future Medicine
Page Range:193-203
Date:August 2019
Official Publication:https://doi.org/10.2217/nmt-2019-0003
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library